Hyogo Medical University is recruiting patients for a PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT06318286, aims to enroll up to 25 participants at 1 sites.
About the Study
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE2
- Sponsor: Hyogo Medical University
- Enrollment target: 25
- Status: RECRUITING
Why This Trial Matters
Study Locations
Contact the trial sponsor for information about participating sites.
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening